We tried to purify a substance exhibiting mitogenicity for human peripheral blood lymphocytes from Yersinia pseudotuberculosis isolated from patients with Y. pseudotuberculosis infection manifesting acute and systemic clinical symptoms. The supernatant of a suspension of the bacteria disrupted by sonication was serially chromatographed on DEAE-Sepharose fast-flow, Sephacryl S-100 HR, and TSK-gel G2000SW high-pressure liquid chromatography columns. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis revealed that the purified mitogenically active substance migrated as a single band corresponding to a molecular mass of 21 kDa. We designated the purified substance Y. pseudotuberculosis-derived mitogen (YPM). YPM stimulated human peripheral T cells to proliferate and produce interleukin-2 at 0.1 ng/ml or more.
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YPM-induced T-cell activation required the expression of HLA class H molecules on accessory cells.
Yersiniapseudotuberculosis, a gram-negative bacillus, has been shown to cause an infectious disease manifesting acute and systemic clinical symptoms (8, 10, 11, 15, 17) . In particular, mass outbreaks of Y pseudotuberculosis infection have often been observed in Japan (10, 11, 17) . It is noteworthy that the clinical symptoms of Y pseudotuberculosis infection are similar to and overlap those of toxic shock syndrome (TSS) (14) caused by exotoxins such as TSS toxin 1 (TSST-1) (2, 12) and a group of staphylococcal enterotoxins (4) or of streptococcal pyrogenic exotoxins (3, 6) . Recently these exotoxins were classified as a group of bacterial superantigens (5, 7, 9) . It has been proposed that superantigenic stimulation of T cells plays a central role in the development of abnormal changes in TSS (9, 20) . Considering the similarity of the clinical symptoms of Y pseudotuberculosis infection and TSS, it would be reasonable to speculate that a certain superantigenic exotoxin is involved in Y pseudotuberculosis infection. In preliminary experiments we found that culture fluids and supernatants of disrupted cells of Y pseudotuberculosis isolated from patients with Y pseudotuberculosis infection contain the mitogenic activity for human peripheral blood lymphocytes (PBL). Purification of this substance would be a key to understanding the pathogenic mechanism of the disease. The above assumption seems to be supported by a recent report indicating that Yersinia enterocolitica, a bacterium related to Y pseudotuberculosis, produces a cell-associated superantigenic substance (16) .
Therefore, we purified this mitogenic substance from Y pseudotuberculosis isolated from patients with a Y pseudotuberculosis infection. We found that the bacteria produce a 21-kDa substance which exhibits marked ability to activate human T cells (designated Y pseudotuberculosis-derived mitogen [YPM] ). In this study we present data on the entire process of YPM purification and several requirements for T-cell activation by it. * Corresponding author.
MATERIALS AND METHODS
Reagents. Brain heart infusion broth was purchased from Difco Laboratories (Detroit, Mich.). RPMI 1640 culture medium used for culture of lymphoid cells contained 100 ,ug of streptomycin per ml, 100 U of penicillin per ml, 10% fetal calf serum, and 5 x 10' M 2-mercaptoethanol. Streptomycin used for nucleic acid precipitation was provided by Meiji Seika Co., Ltd., Tokyo, Japan. Monoclonal antibody (MAb) I2C3 (reactive with HLA-DR/DP) was used in the ascitic form as reported previously (18) . TSST-1 was purified from the culture fluid of Staphylococcus aureus FRI 1169, as reported previously (1) .
Yersinia strain. Strain CYP86-15, serotype 4b, a Y pseudotuberculosis strain isolated from patients in a mass outbreak of Y pseudotuberculosis infection in Shisui Town, Chiba Prefecture, Japan, in March 1986 (10), was kindly provided by Kenji Koiwai, Chiba Institute of Health Science, and used for purification of the exotoxin.
Purification of the mitogenic substance. The activity of the target substance was monitored by measuring its mitogenicity for human PBL through the entire process of purification.
Protein concentration was monitored by measuring the A280 or with the Bio-Rad protein assay system (Nippon Bio-Rad Laboratories, Tokyo, Japan). The bacteria (Y pseudotuberculosis CYP86-15) were grown in 20 liters of brain heart infusion broth for 18 h at 27°C (yield, 40 g [wet weight] per culture). Twenty grams of the bacteria, collected by a continuous centrifuge (Hitachi Koki Co., Ltd., Tokyo, Japan), was suspended in 200 ml of phosphate-buffered saline (PBS) (pH 7.2) and ultrasonicated. The supernatant of the suspension of disrupted cells was depleted of nucleic acids by adding streptomycin at 3% and removing the precipitates by centrifugation after extensive dialysis against distilled water, as reported by others (13) . The supernatant was then depleted of the unprecipitated substances by precipitation with 100%-saturated ammonium sulfate. The precipitate was dissolved in distilled water and then desalted by applying it on a Sephadex G-25 (Pharmacia LKB Biotechnology, Tokyo, Japan) column equilibrated with 25 mM monoethanolamine-chloride (pH 9.0) (150 ml). As nucleic acids contained in the supernatant moved together with proteins, including the mitogenic substance, in the chromatography used in the present study, their removal by the streptomycin treatment markedly helped the subsequent steps of purification. The precipitation with 100% ammonium sulfate increased threefold the specific activity of the mitogenic substance in the supernatant, as shown later (see Table 1 ). The desalted sample, diluted a further fourfold with distilled water, was chromatographed on a DEAE-Sepharose fast-flow (Pharmacia LKB Biotechnology) column (2.6 by 20 cm) equilibrated with 25 mM monoethanolamine-chloride (pH 9.0). Elution was performed with a linear gradient of 0 to 0.2 M NaCl in the same buffer. The mitogenically active fractions were pooled, concentrated 10-fold with a Concentrator EC-10 (Tomy Seiko Co., Ltd., Tokyo, Japan), and chromatographed on a Sephacryl S-100 HR (Pharmacia LKB Biotechnology) column (2.6 by 92 cm) equilibrated with 0.1 M NH4HCO3. The mitogenically active fractions were 2.0
pooled, concentrated fivefold with the concentrator, and chromatographed on a TSK-gel G2000SW high-pressure liquid chromatography (HPLC) (Tosoh Co. Ltd., Tokyo, Japan) column (2.15 by 30 cm) equilibrated with PBS (pH 7.2). After the entire purification procedure, 22 tg of YPM was obtained.
Bacteria incubated at 37°C also produced the mitogenic substance. However, the mitogenic substance was produced in slightly larger amounts at 27°C than at 37°C. A mitogenic activity was detected in the culture fluids of the bacterium. It was eluted at the same molecular mass (21 kDa) as that in the disrupted cells in a Sephacryl S-100 column. Polyclonal antibodies obtained by immunizing rabbits with YPM from the disrupted cells completely inhibited the mitogenic activity of the culture fluid. In light of above observations, the molecule exhibiting mitogenic activity in the culture fluid seems to be identical to that in the disrupted cells. We chose the disrupted cells for YPM purification, because various substances contained in the culture fluids disturbed the purification of the mitogenic substance in the culture super- Fig. 1 Human lymphoid cells and L-cell transfectants. Preparation of several fractions of human lymphoid cells was described previously (18, 20) . Briefly, human PBL were obtained from heparinized peripheral blood of healthy donors by FicollConray density gradient centrifugation. T-cell-depleted human PBL were obtained by the S-2-aminoethylisothiouronium-treated sheep erythrocyte rosette method as the nonrosette-forming cell fraction. Assay for IL-2 activity. Cells were stimulated with mitogens in 0.5-ml volumes in 48-well culture plates (Becton Dickinson Labware, Oxnard, Calif.) for various periods. Culture supernatants were examined for interleukin-2 (IL-2) activity by using IL-2-dependent CTLL-2 cells, as described previously (19) . Data are presented as units of IL-2 per milliliter.
RESULTS AND DISCUSSION
Purification of a substance exhibiting mitogenicity for human PBL. The disrupted-cell supernatant was treated with 3% streptomycin sulfate to remove nucleic acids and precipitated with 100%-saturated ammonium sulfate to remove the unprecipitated substances. These treatments helped the subsequent purification procedures and slightly increased the specific activity of the mitogenic activity (Table 1) . First, the precipitated mitogenically active fraction in the ammonium sulfate saturation was chromatographed on a DEAESepharose fast-flow column. Several protein peaks were obtained, and the mitogenic activity was eluted in the first protein peak, corresponding to a position of 90 mM NaCl (Fig. 1) . Second, the pool of fractions from tubes 87 to 104 was chromatographed on a Sephacryl S-100 HR column. Two protein peaks, large and small, were obtained. Interest- ingly, the mitogenic activity was eluted only in the small peak, corresponding to a molecular mass of 19-20 kDa (Fig.  2) . As SDS-PAGE analysis of the pooled sample (tubes 124 to 128) revealed that the fraction contained a major band of 21 kDa and several minor bands of larger and smaller molecular masses, the pooled fraction was chromatographed on a TSK-gel G2000SW column. A single protein peak was obtained, and the mitogenic activity was eluted together with the protein peak (data not shown). SDS-PAGE analysis of the peak fraction revealed that the fraction contained a single band corresponding to a molecular mass of 21 kDa (Fig. 3) . Extraction of mitogenic actity from a gel in SDS-PAGE. In order to ascertain that this 21-kDa molecule is the mitogenic entity, the mitogenically active sample obtained from the Sephacryl S-100 HR chromatography was subjected to SDS-PAGE in duplicate. One lane was stained with Coomassie brilliant blue R-250. The other lane was sliced into 29 fractions and examined for the mitogenic activity. The results showed that the mitogenic activity was eluted from fractions corresponding to a molecular mass of 21 kDa (Fig.  4) . The results obtained from the gel chromatography (Fig. 2) and SDS-PAGE analysis (Fig. 3 and 4) indicate that the mitogenic substance purified in the present study is present as a 21-kDa simple protein in the natural condition, not composed of several subunits. We designated the 21-kDa substance YPM.
Typical results in the entire steps of YPM purification are summarized in Table 1 . When calculated on the basis of specific activity, YPM in the last step of the purification procedure was purified 3,000-fold from the crude cell supernatant ( Table 1) . Analysis of the sequence of the first 18 N-terminal amino acids of YPM revealed that proteins containing the identical or similar sequence have never been reported (data not shown), suggesting that YPM is a novel bacterial product. We believe that YPM is secreted outside of the bacterium. A mitogenic activity detected in the culture fluids was blocked by polyclonal antibodies to YPM and was eluted at the same fraction as YPM (21 kDa) in a Sephacryl S-100 column. So far we do not know whether the more common serotypes (serotypes 1, 2, and 3) of Y pseudotuberculosis also produce YPM. Experiments on this issue are now under way.
Then, we investigated biological activities of YPM for human PBL. Characterization of the biological activities of YPM would be a clue for understanding of the Y pseudotuberculosis infection.
Ability of YPM to activate human T cells. Initially YPM was examined for its mitogenic activity for human PBL. Whole and T-cell-depleted human PBL were stimulated in vitro with various doses of YPM for various days and examined for [3H]thymidine uptake. A substantial level of response was induced at 0.1 ng or more of YPM per ml, and the response reached a plateau at 100 ng/ml on day 3 of stimulation in whole human PBL, while no response at all was induced in T-cell-depleted PBL over the range of YPM doses examined (Fig. 5A) . The time course of the mitogenic response is shown in Fig. SB . A substantial level of response was detected on day 2 of stimulation in whole PBL, and the response continued to increase during the period examined, while no response at all was induced in T-cell-depleted PBL In the absence of YPM, IL-2 production in each culture was less than 0.1 U/ml in panel B.
over the same periods. These results indicate that YPM is a potent T-cell mitogen.
Next, YPM was examined for its ability to induce IL-2 production by human PBL. Whole and T-cell-depleted PBL were stimulated in vitro with various doses of YPM for various hours and examined for IL-2 production. A substantial level of IL-2 was induced at 0.1 ng or more of YPM per ml, and IL-2 production reached a plateau at 10 ng/ml on 24 h of stimulation in whole human PBL, while the response was not induced at all in T-cell-depleted cells over the range of doses of YPM examined (Fig. 6A) . A substantial level of IL-2 production was induced with 10 ng of YPM per ml in a period of stimulation as short as 6 h, and IL-2 production reached a plateau on 24 h of stimulation in whole human PBL, while the response was not induced at all in T-celldepleted PBL over the periods examined (Fig. 6B) . The results indicate that YPM is a potent IL-2 inducer for human T cells.
Requirement of MHC class II molecules on AC in T-cell activation by YPM. It is well known that T-cell activation by exotoxins bearing superantigenic properties such as TSST-1 requires expression of major histocompatibility complex (MHC) class II molecules on AC (7, 9, 18, 21, 22 (5, 7, 9) . In addition, it has been well established that expression of MHC class II molecules on AC is a prerequisite for T-cell activation by bacterial superantigens (7, 9, 18, 21, 22) . The biological entity of YPM described above satisfies the requirements for a bacterial superantigen.
So far we do not know the exact genetic locus encoding YPM. Experiments are now under way to determine whether the locus is encoded by a plasmid and to determine the entire DNA sequence encoding the YPM molecule. 
